Cantor Fitzgerald Predicts XENE FY2026 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Xenon Pharmaceuticals in a report released on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the biopharmaceutical company will earn ($3.58) per share for the year. The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.90) by $0.07. The business had revenue of $7.50 million during the quarter, compared to the consensus estimate of $1.64 million. During the same period last year, the company earned ($0.62) earnings per share.

A number of other brokerages have also issued reports on XENE. The Goldman Sachs Group decreased their price target on Xenon Pharmaceuticals from $60.00 to $52.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. William Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a research report on Monday, May 5th. HC Wainwright reiterated a "buy" rating and set a $53.00 price objective on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Chardan Capital restated a "buy" rating and issued a $55.00 target price on shares of Xenon Pharmaceuticals in a report on Tuesday, May 13th. Finally, Evercore ISI assumed coverage on Xenon Pharmaceuticals in a report on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 target price for the company. One research analyst has rated the stock with a sell rating and twelve have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $54.82.

Xenon Pharmaceuticals Stock Up 0.3%

NASDAQ XENE traded up $0.10 on Tuesday, reaching $32.26. 1,124,944 shares of the stock traded hands, compared to its average volume of 555,016. The firm's fifty day simple moving average is $32.75 and its 200 day simple moving average is $36.56. The company has a market cap of $2.48 billion, a price-to-earnings ratio of -11.44 and a beta of 1.09. Xenon Pharmaceuticals has a 12 month low of $26.74 and a 12 month high of $46.00.

Hedge Funds Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. increased its position in Xenon Pharmaceuticals by 21.9% during the first quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock worth $65,000 after buying an additional 351 shares during the last quarter. Natixis Advisors LLC increased its position in Xenon Pharmaceuticals by 1.9% during the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock worth $806,000 after buying an additional 456 shares during the last quarter. Occudo Quantitative Strategies LP increased its position in Xenon Pharmaceuticals by 5.8% during the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock worth $448,000 after buying an additional 630 shares during the last quarter. Geode Capital Management LLC increased its position in Xenon Pharmaceuticals by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 69,529 shares of the biopharmaceutical company's stock worth $2,726,000 after buying an additional 720 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals during the first quarter worth $30,000. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.